[1]
Nanau, R.M. et al. 2014. Risk of Infections of Biological Therapies with Accent on Inflammatory Bowel Disease. Journal of Pharmacy & Pharmaceutical Sciences. 17, 4 (Oct. 2014), 485–531. DOI:https://doi.org/10.18433/J3GG6D.